Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cytokine Storm Combined with Humoral Immune Response Defect in Fatal Hemorrhagic Fever with Renal Syndrome Case, Tatarstan, Russia.
Garanina E, Martynova E, Davidyuk Y, Kabwe E, Ivanov K, Titova A, Markelova M, Zhuravleva M, Cherepnev G, Shakirova VG, Khaertynova I, Tarlinton R, Rizvanov A, Khaiboullina S, Morzunov S. Garanina E, et al. Among authors: khaertynova i. Viruses. 2019 Jul 2;11(7):601. doi: 10.3390/v11070601. Viruses. 2019. PMID: 31269734 Free PMC article.
Serum Cytokine Alterations Associated with Age of Patients with Nephropathia Epidemica.
Shakirova V, Khaertynova I, Markelova M, Tarlinton R, Behnke J, Martynova E, Garanina E, Rizvanov A, Khaiboullina S. Shakirova V, et al. Among authors: khaertynova i. Biomed Res Int. 2022 Jan 11;2022:4685288. doi: 10.1155/2022/4685288. eCollection 2022. Biomed Res Int. 2022. PMID: 35059462 Free PMC article. Clinical Trial.
Neutralizing Antibodies in COVID-19 Serum from Tatarstan, Russia.
Hamza S, Martynova E, Garanina E, Shakirova V, Bilalova A, Moiseeva S, Khaertynova I, Ohlopkova O, Blatt N, Markelova M, Khaiboullina S. Hamza S, et al. Among authors: khaertynova i. Int J Mol Sci. 2023 Jun 15;24(12):10181. doi: 10.3390/ijms241210181. Int J Mol Sci. 2023. PMID: 37373331 Free PMC article.
Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors.
Hammitt LL, Quinn D, Janczewska E, Pasquel FJ, Tytus R, Reddy KR, Abarca K, Khaertynova IM, Dagan R, Dawson R, McCauley J, Shekar T, Fu W, Pedley A, Sterling T, Tamms G, Musey L, Buchwald UK. Hammitt LL, et al. Among authors: khaertynova im. Hum Vaccin Immunother. 2023 Dec 31;19(1):2177066. doi: 10.1080/21645515.2023.2177066. Epub 2023 Mar 2. Hum Vaccin Immunother. 2023. PMID: 36864601 Free PMC article. Clinical Trial.
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial.
Johnson MG, Strizki JM, Brown ML, Wan H, Shamsuddin HH, Ramgopal M, Florescu DF, Delobel P, Khaertynova I, Flores JF, Fouche LF, Chang SC, Williams-Diaz A, Du J, Grobler JA, Paschke A, De Anda C. Johnson MG, et al. Among authors: khaertynova i. Infection. 2023 Oct;51(5):1273-1284. doi: 10.1007/s15010-022-01959-9. Epub 2023 Jan 17. Infection. 2023. PMID: 36648627 Free PMC article. Clinical Trial.
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.
Wedemeyer H, Schöneweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T, Sagalova O, Chulanov V, Osipenko M, Morozov V, Geyvandova N, Sleptsova S, Bakulin IG, Khaertynova I, Rusanova M, Pathil A, Merle U, Bremer B, Allweiss L, Lempp FA, Port K, Haag M, Schwab M, Zur Wiesch JS, Cornberg M, Haefeli WE, Dandri M, Alexandrov A, Urban S. Wedemeyer H, et al. Among authors: khaertynova i. Lancet Infect Dis. 2023 Jan;23(1):117-129. doi: 10.1016/S1473-3099(22)00318-8. Epub 2022 Sep 13. Lancet Infect Dis. 2023. PMID: 36113537 Clinical Trial.
Antibody and T Cell Immune Responses to SARS-CoV-2 Peptides in COVID-19 Convalescent Patients.
Garanina E, Hamza S, Stott-Marshall RJ, Martynova E, Markelova M, Davidyuk Y, Shakirova V, Kaushal N, Baranwal M, Khaertynova IM, Rizvanov A, Foster TL, Khaiboullina S. Garanina E, et al. Among authors: khaertynova im. Front Microbiol. 2022 Apr 18;13:842232. doi: 10.3389/fmicb.2022.842232. eCollection 2022. Front Microbiol. 2022. PMID: 35509311 Free PMC article.
Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY).
Hammitt LL, Quinn D, Janczewska E, Pasquel FJ, Tytus R, Rajender Reddy K, Abarca K, Khaertynova IM, Dagan R, McCauley J, Cheon K, Pedley A, Sterling T, Tamms G, Musey L, Buchwald UK. Hammitt LL, et al. Among authors: khaertynova im. Open Forum Infect Dis. 2021 Dec 18;9(3):ofab605. doi: 10.1093/ofid/ofab605. eCollection 2022 Mar. Open Forum Infect Dis. 2021. PMID: 35146039 Free PMC article.
Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19.
Arribas JR, Bhagani S, Lobo SM, Khaertynova I, Mateu L, Fishchuk R, Park WY, Hussein K, Kim SW, Ghosn J, Brown ML, Zhang Y, Gao W, Assaid C, Grobler JA, Strizki J, Vesnesky M, Paschke A, Butterton JR, De Anda C. Arribas JR, et al. Among authors: khaertynova i. NEJM Evid. 2022 Feb;1(2):EVIDoa2100044. doi: 10.1056/EVIDoa2100044. Epub 2021 Dec 16. NEJM Evid. 2022. PMID: 38319178
23 results